Ultime notizie per Vaxart (NASDAQ:VXRT) Azioni

Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Inc

Telsey analyst Dana Telsey lowered the price forecast for Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) from $10 to $9, while <a target="_blank" href="https://www.benzinga.com/quote/KSS/analyst-ratings" rel="noreferrer noopener">retaining a Market Perform rating</a>.
On Thursday, the company announced the termination of CEO&nbsp;Ashley Buchanan for cause and appointed Board Chair&nbsp;<a target="_blank" href="https://www.benzinga.com/news/25/05/45138986/kohls-kss-stock-rises-on-ceo-shakeup-preliminary-q1-outlook" rel="noreferrer noopener">Michael Bender</a><a target="_blank" href="https://www.benzinga.com/news/25/05/45138986/kohls-kss-stock-rises-on-ceo-shakeup-preliminary-q1-outlook" rel="noreferrer noopener"> as Interim CEO</a>.
Also, Kohl&#8217;s issued&nbsp;preliminary first-quarter 2025 results, expecting comparable sales to decline between 4.3% and 4.0%, operating income between $40 million and $45 million, and diluted EPS of a loss of <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">20 cents to a loss of 24 cents</a>.
The analyst writes that the CEO position at Kohl&#8217;s appears to have been difficult to maintain since Michelle Gass&#8217;s departure in late 2022.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/initiation/25/04/45048769/barclays-flags-macys-kohls-risks-during-consumer-weakness-highlights-gildan-levis-for-strength" rel="noreferrer noopener">Barclays Flags Macy&#8217;s, Kohl&#8217;s Risks During Consumer Weakness; Highlights Gildan, Levi&#8217;s For Strength</a>
The retailer has faced headwinds, experiencing market share losses over the last several years, even with positive developments like the introduction of Sephora shop-in-shops and Babies&#8221;R&#8221;Us, adds the analyst.
Telsey writes that Kohl&#8217;s has lost ground to off-price retailers, which offer a straightforward value proposition, and e-commerce platforms such as Amazon, due to their convenience and rapid delivery.
The analyst further says that despite the leadership change, Kohl&#8217;s anticipates continuing Buchanan&#8217;s strategies (curated assortment, value/quality, frictionless experience) under the interim CEO.
New leadership will likely focus on stabilization, but consumer recovery will take time, adds the analyst.
Investors can gain exposure to the stock via&nbsp;First Trust DJ Global Select Dividend (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FGD#NYSE">FGD</a>) and Invesco Exchange-Traded Fund Trust II Invesco S&amp;P SmallCap 600 Revenue ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWJ#NYSE">RWJ</a>).
Price Action: KSS shares are up 4.37% at $7.53 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44630572/kohls-shares-tumble-but-analyst-sees-promise-in-new-ceos-strategy" target="_blank" rel="noreferrer noopener">Kohl&#8217;s Shares Tumble, But Analyst Sees Promise In New CEO&#8217;s Strategy</a></li>
</ul>
Photo: Shutterstock

Equities

News

Price Target

Reiteration

Small Cap

Analyst Ratings

Trading Ideas

First Trust Dow Jones Global Select Dividend Index Fund

No Quick Fix for Kohl's: Analyst Highlights Challenges Despite Leadership Change

Shares of ProShares UltraPro Short QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQQQ#NASDAQ">SQQQ</a>) fell 5.03% to $28.52 on Friday, as a strong rally in technology stocks and upbeat <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45164558/us-adds-177000-jobs-in-april-topping-forecasts-as-economy-navigates-tariff-impact">U.S. economic data</a> weighed heavily on the ETF.
What To Know: SQQQ is designed to deliver three times the inverse of the daily performance of the Nasdaq-100 Index, making it a popular vehicle for traders betting against large-cap tech.
The fund's losses came as the Nasdaq-100 surged to its highest level since March, driven by a <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45172683/wall-street-eyes-9th-straight-day-of-gains-apple-falls-as-chinese-sales-disappoint-whats-driving-markets-friday">broad-based risk rally</a>. The S&amp;P 500 extended its winning streak to nine sessions, boosted by solid corporate earnings and a stronger-than-expected April jobs report. 
Nonfarm payrolls rose by 177,000, <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45164558/us-adds-177000-jobs-in-april-topping-forecasts-as-economy-navigates-tariff-impact">easily beating</a> the 130,000 estimate, helping ease investor concerns over economic fallout from new tariffs.
Despite a pullback in Apple shares, other mega-cap tech names advanced, contributing to Nasdaq strength. Treasury yields <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45172683/wall-street-eyes-9th-straight-day-of-gains-apple-falls-as-chinese-sales-disappoint-whats-driving-markets-friday">jumped</a> and the U.S. dollar meanwhile weakened, further diminishing the appeal of defensive positioning.
Read Also: <a href="https://www.benzinga.com/25/05/45173760/whats-going-on-with-roku-stock-friday">What&#8217;s Going On With Roku Stock Friday?</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SQQQ has a 52-week high of $61.60 and a 52-week low of $26.21.
<a href="https://www.benzinga.com/news/24/12/42562050/why-nasdaq-100-inverse-etf-sqqq-is-moving"></a>
<a href="https://www.benzinga.com/news/24/12/42562050/why-nasdaq-100-inverse-etf-sqqq-is-moving"></a>
<a href="https://www.benzinga.com/news/24/12/42562050/why-nasdaq-100-inverse-etf-sqqq-is-moving"></a>

SQQQ

Nasdaq-100 Inverse ETF SQQQ Drops Friday As Tech Rally Pressures Bearish Bets

Needham analyst Scott Berg slashed the price forecast for Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) from $52 to $40 <a href="https://www.benzinga.com/quote/FIVN/analyst-ratings" target="_blank" rel="noreferrer noopener">while retaining a Buy rating</a>.
On Thursday, the company reported first-quarter revenue growth of 13% year-on-year to $279.70 million, beating the analyst consensus estimate of $272.39 million. Adjusted EPS of $0.62&nbsp;topped the <a target="_blank" href="https://www.benzinga.com/25/05/45170256/five9-shares-surge-on-solid-q1-results-and-optimistic-full-year-outlook" rel="noreferrer noopener">analyst consensus estimate of $0.48</a>.
Five9 expects second-quarter revenue of $274.5 million-$275.5 million (versus analyst consensus estimate of $275.22 million) and adjusted EPS of $0.64-$0.66 versus analyst <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">consensus estimate of $0.56</a>.
The analyst writes that Five9 reported strong results, countering a short narrative of slowing deals.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44986369/this-five9-analyst-slashes-forecasts-ahead-of-1q-results" rel="noreferrer noopener">This Five9 Analyst Slashes Forecasts Ahead Of Q1 Results</a>
Positive sales commentary included the best install base growth in three years, with some large deals slipping (one signed in the second quarter), adds the analyst.
Berg notes that strong growth in AI booking and enterprise AI revenues remained a tailwind.
Also, the analyst writes that he sees potential upside beyond this from increased AI adoption driven by product and GTM investments.
Berg added that updated guidance indicates subscription revenue growth likely bottoms in the first half and re-accelerates in the second half.
Price Action: FIVN shares are up 1.32% at $25.41 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44648656/five9-leans-into-artificial-intelligence-while-it-cuts-workforce" target="_blank" rel="noreferrer noopener">Five9 Leans Into Artificial Intelligence While It Cuts Workforce</a></li>
</ul>
Photo: Shutterstock

FIVN

A Cautious 'Buy' - Analyst Lowers Five9 Target Despite Impressive Q1 Results

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>)&nbsp;aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26 <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">from September 26</a>.
The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company's proposed Risk Evaluation and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Mitigation Strategy (REMS)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach</a>
Following pre-NDA discussions with the FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for&nbsp;aficamten in oHCM without an accompanying REMS, and the FDA <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45150594/cytokinetics-announces-new-pdufa-date-for-aficamten-in-obstructive-hypertrophic-cardiomyopathy" rel="noreferrer noopener">accepted the NDA for filing</a>.
Recently, during the NDA review, the FDA requested that Cytokinetics submit a REMS, based on the inherent characteristics of&nbsp;aficamten, which the company provided.
The submission of a REMS has now been determined by FDA to be a Major Amendment to the NDA resulting in a standard three-month extension to the original PDUFA action date.
No additional clinical data or studies have been requested on Cytokinetics by the FDA.
"We remain confident in the distinct benefit-risk and pharmaceutic profile of&nbsp;aficamten and continue to expect a differentiated label and risk mitigation profile upon its potential approval by FDA," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "
In April, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) released topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos&nbsp;(mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44825297/why-us-pharma-giant-bristol-myers-squibb-stock-trading-lower-on-tuesday" rel="noreferrer noopener">hypertrophic cardiomyopathy (nHCM)</a>.
The trial did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44801468/bristol-myers-squibb-provides-update-on-phase-3-odyssey-hcm-trial" rel="noreferrer noopener">consumption (pVO2)</a>.
In January, a Stifel analyst wrote that Cytokinetics appears well-positioned to capitalize on Bristol Myers' groundwork with its second-to-market drug, Alicante, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms <a target="_blank" href="https://www.benzinga.com/25/01/43143013/analyst-optimistic-about-cytokinetics-heart-drugs-future-despite-ma-hurdles-and-royalty-deal-concerns" rel="noreferrer noopener">(Q6M echos) as a standard</a>.
Price Action: CYTK stock is down 16.5% at $35.85 at the last check Friday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-asthma" target="_blank" rel="noreferrer noopener">AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

CYTK

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

Offerings

MGIC Investment Corp Files For Mixed Shelf; Size Not Disclosed

TD Securities analyst Andrew Charles maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Hold and lowers the price target from $14 to $13.

TD Securities Maintains Hold on Wendy's, Lowers Price Target to $13

Goldman Sachs analyst Christine Cho on Thursday <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">reiterated a Neutral</a> rating on the shares of McDonald&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) and raised the price forecast to $345.
McDonald&#8217;s shares dipped 1.9%, underperforming the S&amp;P 500 despite meeting earnings expectations due to disappointing sales trends in both U.S. and international markets.
McDonald&#8217;s U.S. <a href="https://www.benzinga.com/25/05/45135213/mcdonalds-q1-revenue-decline-34-as-war-in-the-middle-east-bites-stock-dips">sales fell 3.6% in first-quarter</a>, below expectations, due to weaker traffic from lower and middle-income groups. Yet, upper-income spending remained strong.
The $5 meal deal is driving traffic and will be extended through year-end, although other value offers like Buy-One-Add-One-For-$1 are underperforming, noted the analyst.
Management expects first-quarter to be the year&#8217;s low point, with momentum building from promotions like the Minecraft Movie tie-in and upcoming menu additions including McCrispy strips and snack wraps.
Also Read: <a href="https://www.benzinga.com/news/25/05/45166629/wendys-q1-misses-revenue-estimate-lowers-2025-outlook-amid-us-sales-dip">Wendy&#8217;s Sizzles Abroad, But US Sales Leave Investors Cold</a>
McDonald's international operations continue to face headwinds, with a strategic focus on value offerings to maintain and grow market share.
The International Operated Markets (IOM) segment posted a 1.0% decline in same-store sales, falling short of analyst expectations. The company cited weak consumer traffic in France, Germany, and Australia, although it outperformed competitors in those regions.
France recorded its first market share gain in three years.
Meanwhile, the International Developmental Licensed Markets (IDLM) segment grew 3.5%, exceeding estimates. In the Middle East, Japan, and China, delivery expansion, affordable meal options, and chicken offerings drove results.
Management said global brand sentiment remains steady. Anti-American sentiment has reportedly risen in parts of Northern Europe and Canada. Chicago-based McDonald's hasn&#8217;t seen an impact in sales data.
McDonald's posted an operating margin of 45.6% for the quarter. That&#8217;s up 110 basis points year over year and matches analyst expectations.
This improvement was largely attributed to reduced SG&amp;A expenses, helped by delayed investments in digital and tech.
Price Action: McDonald&#8217;s shares traded lower by 0.47% at $312.17 at last check Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45170433/kimberly-clark-commits-2b-to-us-expansion-overhaul">Kimberly-Clark Commits $2 Billion For US Expansion Overhaul</a></li>
</ul>

Restaurants

McDonald's Stumbles On Weak Traffic, Despite Margin Gains And Analyst Optimism

The U.S. stock market staged a stunning one-month rebound, fully erasing the losses triggered by Donald Trump&#8216;s <a href="https://www.benzinga.com/topic/donald-trump">April 2 tariff announcements.</a>
From its April low of 4,835 points, the S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—has surged 17.5%, logging nine consecutive sessions of gains through Friday, the longest winning streak since May 2024.
Still, the rally has been far from uniform across sectors.
The sectoral rebound since April has been powerful, but only a handful of sectors have managed to fully recover to or exceed their April 2 levels, before Trump&#8217;s tariff announcements triggered a broad selloff.
Technology led the charge, surging 25.9% since the April low and now stands 3.8% above its April 2 level, the strongest full recovery among all major sectors.
Industrials and Utilities also climbed 1.8% and 1% above their early-April levels, respectively.
Sectors like Consumer Discretionary , Communication Services, Financials, Consumer Staples, and Real Estate posted strong double-digit rebounds off April lows—ranging from 8.3% to 18.9%— finally reaching April 2 levels without breaching them.
On the other end of the spectrum, Energy remains 13.4% below its April 2 level, making it the worst laggard. Health Care is still down 4% from early April, even after recovering 7.2%. Materials also underperformed, ending the period 1.9% below its pre-tariff announcement level.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Sector</th>
<th>%chg since April lows</th>
<th>May 2 vs. April 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>16.1%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>8.3%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>16.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>11.3%</td>
<td>-13.4%</td>
</tr>
<tr>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>18.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>7.2%</td>
<td>-4%</td>
</tr>
<tr>
<td>Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>20.4%</td>
<td>up by 1.8%</td>
</tr>
<tr>
<td>Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>16.4%</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>17.2%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>25.9%</td>
<td>up by 3.8%</td>
</tr>
<tr>
<td>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>12.2%</td>
<td>up by 1%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top Performing S&amp;P 500 Stocks Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td>Information Technology</td>
<td>41.22%</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>Communication Services</td>
<td>23.45</td>
</tr>
<tr>
<td>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>)</td>
<td>Industrials</td>
<td>23.16</td>
</tr>
<tr>
<td>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)</td>
<td>Industrials</td>
<td>20.78</td>
</tr>
<tr>
<td>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>Information Technology</td>
<td>18.92</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>Information Technology</td>
<td>18.87</td>
</tr>
<tr>
<td>ServiceNow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</td>
<td>Information Technology</td>
<td>18.80</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst Performer Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Information Technology</td>
<td>-26.66%</td>
</tr>
<tr>
<td>Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>Health Care</td>
<td>-25.89</td>
</tr>
<tr>
<td>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>Health Care</td>
<td>-23.76</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>Energy</td>
<td>-21.40</td>
</tr>
<tr>
<td>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>Financials</td>
<td>-20.95</td>
</tr>
<tr>
<td>Targa Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>)</td>
<td>Energy</td>
<td>-20.79</td>
</tr>
<tr>
<td>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>Health Care</td>
<td>-20.00</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45174409/nasdaq-100-leveraged-etf-tqqq-surges-55-as-tech-rally-jobs-data-boost-risk-appetite">Nasdaq-100 Leveraged ETF TQQQ Surges 5.5% As Tech Rally, Jobs Data Boost Risk Appetite</a></li>
</ul>
Photo: Shutterstock

Markets

AVGO

CRWD

ENPH

NFLX

PLTR

TRGP

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?

<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>TSG Consumer Partners is <a href="https://www.bloomberg.com/news/articles/2025-04-30/tsg-consumer-is-said-to-near-investment-in-cookie-chain-crumbl?sref=TBDibEcD">reportedly</a> eyeing a sweet deal—a minority stake in Crumbl, the Utah-based cookie empire that could be worth a jaw-dropping $2 billion. Meanwhile, Blackstone and Golub Capital are cooking up something too, whipping together a $500 million unitranche loan to help fuel Crumbl's dough-powered expansion. Apparently, big money has a serious sweet tooth.</li>
</ul>
<ul>
<li>HistoSonics—a Johnson &amp; Johnson-backed medtech company—is exploring a sale after drawing interest from several big-name suitors. According <a href="https://www.ft.com/content/cb1c5bf1-ddf8-4c8b-b62d-99c081bce8c6">to</a> the Financial Times, they're aiming for a healthy $2.5 billion valuation. Medical device giants like Medtronic, GE HealthCare and Johnson &amp; Johnson are circling the Ann Arbor-based firm like surgeons around an OR table. The company's non-invasive tech, known as histotripsy—FDA-approved for liver cancer—uses focused ultrasound beams to treat tumors. They&#8217;re testing it next on the kidneys and pancreas. Citigroup is running point on the sale process.</li>
</ul>
<ul>
<li>Blackhawk Network, the prepaid gift card provider, is in a dual-track process. Silver Lake Management and P2 Capital Partners are exploring a potential sale or IPO with a valuation target of over $5 billion, according <a href="https://www.bloomberg.com/news/articles/2025-04-28/silver-lake-p2-weighs-5-billion-plus-exit-of-blackhawk?srnd=phx-deals&amp;sref=TBDibEcD">to</a> Bloomberg.</li>
</ul>
<ul>
<li>Decathlon SA is looking to pass the baton on about 30% of its China business, hoping to raise some cash while keeping its sneakers firmly planted in the country. Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-04-29/decathlon-is-said-to-start-talks-to-sell-stake-in-china-business?srnd=phx-deals&amp;sref=TBDibEcD">reports</a> that the French sporting goods giant has hired an adviser and caught the eye of potential investors—but the deal may hit a speed bump, as some suitors are eyeing more than just a minority stake. If the sale goes through, the China arm could be valued north of $1 billion. Still, Decathlon might just bench the whole idea or try other plays to grow in the market. With over 200 stores and 30-plus years in China, they're not ready to hang up their cleats just yet.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Sony Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) is considering a spin-off of its chip unit, according to Bloomberg. The chip unit earned nearly $12 billion last fiscal year and produces image sensors used in Apple&#8217;s iPhones.</li>
</ul>
<h2 class="wp-block-heading">Off The Block</h2>
<ul>
<li>Clearlake Capital <a href="https://www.prnewswire.com/news-releases/clearlake-capital-completes-majority-investment-in-modmed-to-fund-growth-302442922.html">completed</a> a majority stake in ModMed, a healthcare SaaS company founded in 2010 that uses AI to improve clinical and operational efficiency. ModMed&#8217;s platform includes tools for electronic health records, practice management, revenue cycle management and more. Previous backers include Warburg Pincus, Pentland Capital and Summit Partners.</li>
</ul>
<ul>
<li>Chef Boyardee, the ravioli-in-a-can icon created by Italian chef Hector Boiardi (yes, he was real), has fed generations of microwave-happy Americans. It will now be lovingly tucked into the pantry of Hometown Food Co., a Chicago-based portfolio company owned by Brynwood Partners. The acquisition includes a massive 820,000-square-foot plant in Milton, Pennsylvania. On the sell side is Conagra Brands, which scored $600 million on the sale. Hometown also has Hungry Jack and Pillsbury in its lineup. </li>
</ul>
<ul>
<li>AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) completed its purchase of BlueHalo, a space and defense engineering firm, from Arlington Capital Partners for around $4.1 billion in cash and stock, Reuters reported.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul>
<li>More than 350 Forever 21 stores are set to <a href="https://www.usatoday.com/story/money/2025/04/30/forever-21-closing/83373431007/">close</a> by May 1. The fast fashion chain filed for Chapter 11 bankruptcy in March. According to court documents, all 354 leased U.S. locations will be shuttered. The company had said closures might be halted if a buyer stepped forward. As of April 30, no knight in stylish armor had emerged.</li>
</ul>
<ul>
<li>Biotech firm Molecular Templates has filed for Chapter 11 bankruptcy as it looks to restructure its operations, The Street <a href="https://www.thestreet.com/breaking-news/another-major-healthcare-company-files-for-chapter-11-bankruptcy">reports</a>. Known for developing cancer treatments, the company listed just $2.49 million in assets against a hefty $29.4 million in debt. It's now partnering with lender K2 Health Ventures to keep its research alive—and its lights on.</li>
</ul>
<ul>
<li>Diamond Comic Distributors has found two new buyers—Universal Distribution and Ad Populum. The update comes just a day after its original suitor, Alliance Entertainment, sued the company for alleged fraud. The federal bankruptcy court approved the sale of separate divisions to the new buyers, though the deals haven't closed yet. Diamond, which began in a Baltimore basement in the 1970s, filed for bankruptcy earlier this year. Alliance had bid $85 million in March but claims Diamond inflated its value. The new deals are worth less—$42 million and $7.5 million—pending final conditions. Should it work out, they&#8217;re expected to close by May 14, <a href="https://www.thebaltimorebanner.com/economy/diamond-comics-bankruptcy-STC5ENGBVNGVVIBUQGQSURYIPQ/">per</a> the Baltimore Banner. </li>
</ul>
<h2 class="wp-block-heading">Notes From The Block</h2>
The deal landscape (including IPOs) is getting quiet, but bankruptcy filings are on the rise. 
In April, total individual filings hit 47,323, up 10% year-over-year.
The increase &#8220;reflects the mounting financial strain on households, elevated prices, and higher borrowing costs," <a href="https://www.globenewswire.com/news-release/2025/05/02/3073370/10374/en/April-Consumer-Chapter-7-Bankruptcy-Filings-Increase-16-Percent-from-Previous-Year.html">said</a> Michael Hunter, vice president of bankruptcy data tracker Epiq AACER.
Commercial filings have &#8220;softened,&#8221; but there has been an &#8220;uptick in small business Subchapter V elections,&#8221; or Chapter 11 for small businesses looking to restructure their debts. This &#8220;signals persistent distress among smaller businesses navigating an uncertain economic landscape,&#8221; he said.
April's data comes on the heels of <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44764554/consumer-sentiment-crashes-to-3-year-lows-as-inflation-expectations-spike-to-1981-highs">a bleak consumer sentiment report</a> and heightened inflation expectations.
Small businesses are feeling the sting and &#8220;seeking relief&#8221; via restructuring options, Hunter added.
For the previous edition of <a href="https://www.benzinga.com/news/asset-sales/25/04/45019877/deal-dispatch-jack-in-the-box-to-dump-del-taco-fyre-brand-hits-auction-block-bertuccis-bites-bankruptcy-bullet-again">Deal Dispatch, click here</a>.

AVAV

Sony Group Corporation American Depositary Shares

SONY

Deal Dispatch: Chef Boyardee, Crumbl Appear Tasty To Buyers While Bankruptcies Tick Upward

Shauneen Bruder was unanimously re-elected by the board of directors as board chair. Ms. Bruder is a Corporate Director and retired Executive Vice-President, Operations at the Royal Bank of Canada.

Management

Canadian National Railway's Shauneen Bruder Was Unanimously Re-Elected By The Board Of Directors As Board Chair

RBC Capital analyst Matthew Swanson maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Outperform and lowers the price target from $30 to $25.

ZETA

RBC Capital Maintains Outperform on Zeta Global Holdings, Lowers Price Target to $25

RBC Capital analyst Deane Dray maintains W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) with a Sector Perform and raises the price target from $1097 to $1144.

RBC Capital Maintains Sector Perform on W.W. Grainger, Raises Price Target to $1144

RBC Capital analyst Matthew Swanson maintains Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) with a Sector Perform and lowers the price target from $17 to $16.

THRY

RBC Capital Maintains Sector Perform on Thryv Holdings, Lowers Price Target to $16

RBC Capital analyst Nik Modi maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Sector Perform and lowers the price target from $178 to $175.

RBC Capital Maintains Sector Perform on Hershey, Lowers Price Target to $175

Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) shares rose 4.07% to $150.98 Friday afternoon following Rockstar Games' announcement that Grand Theft Auto VI, originally slated for fall 2025, will now <a href="https://www.benzinga.com/news/25/05/45166208/rockstar-games-delays-highly-anticipated-grand-theft-auto-vi-release">launch</a> in May 2026.
What To Know: The delay of one of the most anticipated titles in gaming history sent Take-Two Interactive Software, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) stock sharply lower, but created a potential ripple of optimism around EA's release calendar. 
Investors appear to be betting that EA, which has avoided directly competing with Rockstar in recent years, could benefit from the <a href="https://www.benzinga.com/pressreleases/25/05/b45162943/take-two-interactive-software-inc-reiterates-expectations-to-achieve-sequential-increases-in-and-r">newly opened window</a> in the critical 2025 holiday season.
Without GTA VI dominating consumer attention this year, EA franchises like FIFA (now EA SPORTS FC), Madden NFL and potentially EA SPORTS College Football 26 could enjoy greater visibility and stronger sales. 
The extra breathing room may also allow EA to capture holiday spending and boost digital engagement without contending with Rockstar's massive cultural footprint. For EA, the absence of GTA VI in 2025 could lead to outperformance during a typically competitive release cycle.
Read Also: <a href="https://www.benzinga.com/news/25/05/45173004/palantir-pltr-stock-is-up-over-400-ahead-of-mondays-earnings-report-whats-going-on">Palantir Stock Is Up Over 400% Ahead of Monday&#8217;s Earnings Report: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy EA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Electronic Arts&#8217; case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, EA has a 52-week high of $168.50 and a 52-week low of $115.21.

TTWO

Electronic Arts (EA) Stock Climbs 4% Amid GTA VI Delay

RBC Capital analyst Nik Modi maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Outperform and lowers the price target from $100 to $90.

RBC Capital Maintains Outperform on Estee Lauder Cos, Lowers Price Target to $90

RBC Capital analyst Shagun Singh maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Sector Perform and lowers the price target from $150 to $145.

RBC Capital Maintains Sector Perform on Teleflex, Lowers Price Target to $145

WIIM

E.L.F Beauty shares are trading higher. The company may be experiencing strength amid reports that China's Commerce Ministry is assessing possible trade talks with the US. This may be significant because most of the company's products are manufactured by third-party suppliers in China.

RBC Capital analyst Matthew McKellar maintains Rayonier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYN#NYSE">RYN</a>) with a Sector Perform and lowers the price target from $28 to $27.

RBC Capital Maintains Sector Perform on Rayonier, Lowers Price Target to $27

RBC Capital analyst Brad Heffern maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Sector Perform and lowers the price target from $329 to $328.

RBC Capital Maintains Sector Perform on Public Storage, Lowers Price Target to $328

Press Releases

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Comments

Vaxart

Notizie

Ultime notizie per Vaxart (NASDAQ:VXRT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO